Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Assets Average (2016 - 2025)

Historic Assets Average for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to $1.2 billion.

  • Ligand Pharmaceuticals' Assets Average rose 3316.94% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 3316.94%. This contributed to the annual value of $864.5 million for FY2024, which is 1155.61% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Assets Average of $1.2 billion as of Q3 2025, which was up 3316.94% from $927.0 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Assets Average ranged from a high of $1.3 billion in Q1 2021 and a low of $763.7 million during Q3 2023
  • Its 5-year average for Assets Average is $1.0 billion, with a median of $927.0 million in 2025.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Assets Average crashed by 3450.3% in 2023, and later skyrocketed by 3316.94% in 2025.
  • Ligand Pharmaceuticals' Assets Average (Quarter) stood at $1.3 billion in 2021, then fell by 29.48% to $906.6 million in 2022, then dropped by 14.16% to $778.2 million in 2023, then rose by 21.86% to $948.3 million in 2024, then rose by 27.88% to $1.2 billion in 2025.
  • Its Assets Average stands at $1.2 billion for Q3 2025, versus $927.0 million for Q2 2025 and $923.6 million for Q1 2025.